2nd convention front cover - ethnopharmacology

National Seminar “Ethnopharmacology: Perspectives for Development of Ayurveda”

March 19, 2016

Organized by: National Research Institute of Ayurvedic

Drug Development (NRIADD) CCRAS, Ministry of AYUSH

Government of India 4- CN Block, Sector –V

Bidhannagar, Kolkata - 700091.

In association with Society for Ethnopharmacology (SFE - INDIA)

23/3 Saktigarh, Kolkata (Affiliated to: International Society for Ethnopharmacology, UK)

www.ethnopharmacology.in

Venue: National Research Institute of Ayurvedic Drug Development (NRIADD) Auditorium, Bidhannagar, Kolkata

Saturday, March 19, 2015

REGISTRATION: 9:00-10:00 AM

INAUGURATION OF THE PROGRAMME: 10:00-11:00 AM

Inaugural song & Lighting of the Lamp

Dr. Jayram Hazra, Director, NRIADD, Kolkata

Dr. Sushanta Banerjee, Director of Medical Education & ex officio Secretary Govt. of West Bengal

Prof. V. K. Joshi, Professor, Benaras Hindu University, Chairman, Ayurveda Pharmacopeia Commission, Govt. of India

Dr. Pratim Banerji, President, Society for Ethnopharmacology, India ,Kolkata

Dr. V Ravichandiran., Director, National Institute of Pharmaceutical Education & Research (NIPER), Kolkata

Mr. Birendra K Sarkar, Vice-President, Society for Ethnopharmacology, India

Prof. Pulok K Mukherjee, Secretary, Society for Ethnopharmacology, India

11:00-11:15 AM

TEA BREAK

http://www.jaduniv.edu.in/�

Session I: 11:15 am - 01:00 pm

Dr. Debprasad Chattopadhyay, SFE-INDIA “Society for Ethnopharmacology, India”

Prof. V. K. Joshi, Professor, Benaras Hindu University, Chairman, Ayurveda Pharmacopeia Commission, Govt. of India

"Ethnopharmacology in Ayurveda-The Traditional Indian Medicine of Ancient Origin"

Prof. Subir Kumar Maulik, Department of Pharmacology, AIIMS, New Delhi " Clinical trials of Aurvedic drugs: need and challenges"

Dr. Prasanta Kumar Sarkar, Director, WB State Medicinal Plant Board “Conservation of medicinal plants for quality Ayurvedic medicine”

01:15 -02:00 pm Lunch break

Session II: 02:00 – 03:20 pm

Dr. Dulal Chandra Pal, Scientist, Parker Robinson Pvt. Ltd., Kolkata

“Traditional Medicine used by the tribes in some part of West Bengal”

Prof. Ambarish Mukherjee, Dept. of Botany, University of Burdwan “Traditional Medicines in Contemporary Health Care Systems”

Prof. Sanmoy Karmakar, SFE-INDIA “Safety issues of herbal drugs”

Dr. Pawan Sharma, Vice President, S.C. Generics, Emami Ltd., Kolkata “Need for research for Ayurvedic industry”

ORAL PRESENTATION: 3:15 – 4:30 PM

Oral presentation should be specific (5 slides max). Best two presentations will be awarded during the valedictory programme.

Evaluators for Oral presentations:

Dr. Achintya Mitra, NRIADD, Kolkata

Dr. Arun Bandyopadhyay, IICB, Kolkata

POSTER PRESENTATION: 3:15 – 4:30 PM

All posters should be mounted at 11 AM in the poster presentation room. The posters will be evaluated during post-lunch session. Best three posters will be awarded during the valedictory programme.

Evaluators for Poster presentations: Dr. S. N. Upadhyay, NRIADD, Kolkata Dr. A. K. Panda, NRIADD, Kolkata Dr. P. K. Haldar, SFE-INDIA Dr. Subhas C. Mandal, SFE-INDIA

VALEDICTORY SESSION & CERTIFICATE DISTRIBUTION: 04:30-5:00 PM

Dr. Jayram Hazra, Director, NRIADD, Kolkata

Dr. Pratim Banerji, President, Society for Ethnopharmacology, India, Kolkata

Dr. R. N. Bhattacharya, Dept. of Plastic Surgery, R. G. Kar Medical College, Kolkata

Mr. B K Sarkar, Vice-President, Society for Ethnopharmacology, India, Kolkata

Dr. Achintya Mitra, Co-ordinator, National Seminar

Dr. D Chattopadhyay, Co-ordinator,National Seminar

Prof. Pulok K Mukherjee, Secretary, Society for Ethnopharmacology, India, Oral & Poster Award Ceremony END of the programme

Organizing committee:

Patron –in- chief : Vd. K.S. Dhiman

Director General, CCRAS, New Delhi

Patrons :

Dr. M.M.Padhi CCRAS, New Delhi

Dr. Pratim Banerji President, SFE-India

Mr. B K Sarkar Vice-president, SFE, India

Mr. Indraneel Das Vice-president, SFE, India

Co-ordinators:

Dr. Achintya Mitra NRIADD, Kolkata

Dr. D. Chattopadhyay Member, SFE-India

Jt. Co-ordinator:

Dr. Sanmoy Karmakar Member, SFE-India

Dr. Pallab Kanti Haldar. Member, SFE-India

Chairman: Dr. Jayram Hazra Director, NRIADD, Kolkata

Co-chairman: Dr. Pulok K Mukherjee Secretary, SFE-India

Members Dr. S.C. Mandal Member, SFE-India

Dr. S. N. Upadhyay NRIADD, Kolkata

Mr. Prabir Banerjee Member, SFE-India

Dr. A.K.Panda NRIADD, Kolkata

Dr. Anjan Saha Member, SFE-India

Dr. R.K.Ravte NRIADD, Kolkata

Dr. Arun Bandopadhyay Member, SFE-India

Dr. L.D. Barik NRIADD, Kolkata

Dr. BP Saha Member, SFE-India

Dr. Debajyoti Das NRIADD, Kolkata

Dr. Santanu Bhadra Member, SFE-India

Dr. K.K.Ratha NRIADD, Kolkata

Mr. Kalyan Hazra NRIADD, Kolkata

Mr. D.N. Mandal NRIADD, Kolkata

Associates of Society for Ethnopharmacology, India

Mr. Amit Kar Mr. Debayan Goswami

Mr. Joydeb Chanda Mr. Shiv Bahadur

Mr. R K Harwansh Mr. Subhadip Banerjee

Mr. Amarendra K Tiwari Mr. Logesh R

MrPritorthi Bhattacharjee Mr. Sayan Biswas

Mr. Sagnik Haldar Mr. Mainak Chakraborty

National Research Institute of Ayurvedic Drug Development CCRAS, Ministry of AYUSH, Government of India

4- CN Block, Sector -V, Bidhannagar, Kolkata - 700091. Fax: 033 2367-1001, EPBX : 033 2367-3881/1002, Ph. 033 2367-3808 (Director)

Email: [email protected] & [email protected]

National Research Institute of Ayurvedic Drug Development (NRIADD) formerly known as Central Research Institute of Ayurveda was established as Regional Research Institute (Ay.) on 1971 at Jagannath Dutta Lane, Kolkata and then the Institute was shifted to Bidhannagar, Kolkata on 1997 in its own building. This Institute is functioning under Central Council for Research in Ayurvedic Sciences, an autonomous research council of Ministry of AYUSH, Government of India. NRIADD, Kolkata is presently having with six departments, named Hospital (OPD & IPD), Pathology & Biochemistry, Pharmacognosy, Chemistry, Pharmacology and Pharmacy. The Pharmacy Department is affiliated as GMP certified by ISM Drug Control, Government of West Bengal and the Animal House under Pharmacology Department is accredited by CPCSEA, Government of India for conducting animal experimental studies. This Institute is also affiliated by West Bengal University of Health Sciences for conducting Ph.D. studies in Ayurveda and Pharmacology. NRIADD, Kolkata has created many new avenues for the drug development particularly in Ayurveda through drug research and clinical studies since inception. This multi-disciplinary conference will provide an ideal platform for interaction, debate, fusion and dissemination of ideas between emerging young researchers, students and professionals. I welcome all of you for your valued participation and interest to make this event successful. I wish you all a very effective scientific interaction and hope to have a meaningful meeting. Dr. Jayram Hazra

Director National Research Institute of Ayurvedic Drug Development (NRIADD) CCRAS, Ministry of AYUSH, Govt. of India 4- CN Block, Sector –V Bidhannagar, Kolkata - 700091.

mailto:[email protected]�

SOCIETY FOR ETHNOPHARMACOLOGY, INDIA [SFE -INDIA] “Globalizing local knowledge and localizing global technologies”

23/3 Saktigarh, Jadavpur, Kolkata 700032 (Affiliated to the International Society for Ethnopharmacology, UK)

Website: www.ethnopharmacology.in

The Society for Ethnopharmacology (SFE) is a registered society under the West Bengal Society Registration act and affiliated to the International Society for Ethnopharmacology (ISE), UK. The ISE is an international scientific organization of researchers dedicated to the interdisciplinary study of the pharmacological actions of plants, animals, insects, and other organisms used in medicines of indigenous and modern, past and present, cultures. The society is also committed to the preservation and conservation of such practices for future generation.

After the grand success of the 12th International Congress of International Society for Ethnopharmacology (ISE) organized by the School of Natural Product Studies, Jadavpur University Kolkata in February 2012, the Society for Ethnopharmacology, India (SFE – India) was constituted in August 2013. The Society is extremely grateful to Late Dr. APJ Abdul Kalam, former President of India, for his inspiration and support for its formation.

The Society for Ethnopharmacology, India (SFE - India) was constituted by the eminent academicians, researchers, industrialists and others with the vision of providing an environment for knowledge sharing among industrialists, researchers, students, healthcare-practitioners, decision-makers and others interested in promotion of Ethnopharmacology and medicinal plant. The mission of the society is promotion and development of traditional medicine and medicinal plants through dissemination of knowledge and development of collaboration and cooperation with the major highlights on

“Globalizing local know ledge and localizing global technologies”

The society organizes conferences, seminars, symposiums, workshops etc in different parts of India for discussion and sharing knowledge on different issues for cultivation, production, quality evaluation, safety, clinical studies, biological screening and several other issues of natural product research. The Society helps in forming bridge between the academia and industry for developing cost effective natural remedies. Presently the Society has several local Chapters with dynamic Coordinators for individual chapters and over 600 members across the country. To recognize the outstanding contribution in the area of medicinal plant research and Ethnopharmacology, the Society has instituted several awards which are conferred during the International congress of the society every year as follows:

1) SFE - Lifetime Achievement Award - “Bisheswar Saha Memorial Award” 2) SFE - Outstanding International Ethnopharmacologist Award - “Pranab Banerji

Memorial Award” 3) SFE - Outstanding National Ethnopharmacologist Award - “Harihar Mukherjee

Memorial Award” 4) SFE - ZANDU Award for Best Research on Plant Drugs 5) SFE - Herbal Industry Leader Award

Affiliated to

http://www.ethnopharmacology.in/�

6) SFE - Outstanding Service Award 7) SFE – Special Recognition Award 8) SFE - Travel Grant Award

For dissemination of knowledge the society has taken several initiatives to organize several workshops, seminars, conferences throughout the year in different parts of India:

- The 2nd International Congress of the Society for Ethnopharmacology (SFEC) was organized by

the Department of Pharmaceutical Sciences, R. T. M. Nagpur University, Nagpur, India, during February 20-22, 2015. Dr. Prakash R. Itanakr, Coordinator of Nagpur local chapter was the organizing secretary of the 2nd International Congress 2015 (www.sfec2015.com). The congress was attended by over 1000 delegates from different countries of the world. SFE-India thanks Dr. Prakash Itankar, Coordinator, SFE-India Nagpur local chapter for organizing this event.

- Several invited lectures by disguised speakers was arranged by the SFE-India, Kolkata on emerging topics on Ethnopharmacology and promotion of medicinal plants by the Society office at Kolkata and also in collaboration with School of Natural Product Studies, Jadavpur university, Kolkata.

- The Guwahati local chapter of SFE-India, organized the 1st Regional Seminar: on “Pharmacovigilance of Natural Products- A Preliminary Approach“organized by Department of Pharmacology, ADR Monitoring Centre, Gauhati Medical College, Guwahati, Assam during September 26, 2015. More than 250 delegates from different parts of Indian particularly north east India attended the programme. SFE-India thanks to Dr. Chandana Baruah, Coordinator, SFE-India Guwahati local chapter for organizing this event.

- The 2nd National Convention of the Society for Ethnopharmacology, India on “Integrated Approaches for Promotion and Development of Herbal Medicine.” was organized by School of Natural Product Studies, Jadavpur University, Kolkata during December 5-6, 2015. The seminar was attended by more than 300 delegates from different parts of India with above 150 oral/poster presentations.

- In the 1st International Conference: “Advances in Asian Medicines (ICAAM - 2016); a Special Programme was organized by the Pune Local chapter of SFE-India on “Ethnopharmacology and Validation of Traditional Medicine” during January 4, 2016 at Pune, India. More than 300 delegates participated in this event with above 100 scientific presentations, which make this event grand success. SFE-India is thankful to Dr. Sathiyanarayanan L., SFE-India Coordinator, Pune Local Chapter for organizing this event successfully.

- Chennai local chapter of SFE-India organized a national conference on “Pharmacovigilance of AYUSH Drugs” during January 19, 2016 at Sri Ramachandra University, Porur, Chennai. This event was a very successful event with the participation of more than 500 delegates from all over the country and above 50 scientific presentations were made. SFE-India is thankful to Dr. D. Chamundeeswari, Coordinator, SFE-India Chennai local chapter for organizing this event.

- The 3rd International Congress of the Society for Ethnopharmacology (SFEC 2016) was organized by National Centre for Natural Resources (NCNR), Pt. Ravishankar Shukla University, Raipur, Chhattisgarh, India, during February 19-21, 2016. Prof. S K Pandey, Vice Chancellor,

Pt. Ravishankar Shukla University was the Chairman, Dr. Atanu K Pati, was the organizing secretary and Dr. Shailendra Saraf, Coordinator, SFE-India, Raipur, Local chapter was the Joint organizing secretary of the 3rd International Congress of SFEC 2016, Raipur (www.sfec2016raipur.com).

- The society is publishing the News letter regularly in different aspects for development and promotion of medicinal plants and Ethnopharmacology. We are very excited by the keen interest of our members of SFE from a diverse number of institutes and industries throughout the country to share the knowledge in this regard.

With our limited strength and esteemed efforts and keen interest of our members several institutes and industries throughout the country we are trying to develop coordination and cooperation for promotion of ethnopharmacological aspects by sharing the knowledge through multitude of platforms that we present annually in all the nooks and corners of the country at the local, the national as well as the international podium, presenting the opportunity to all to partake in the knowledge exchange process. We encourage new members to join us in our efforts of making a healthier tomorrow, capitalizing on the very rich heritage and culture that is so ethnic, so ancient and yet so Indian.

We are happy to welcome you all to the National Seminar on “Ethnopharmacology: Perspectives for Development of Ayurveda” at National Research Institute of Ayurvedic Drug Development (NRIADD) Auditorium, Bidhannagar, Kolkata on March 19, 2016. We thank to the organizing committee and especially to Dr. J Hazra, Director, NRIADD, Chairman, Dr. Achintya Mitra, Coordinator of the National Seminar from NRIADD, Kolkata. We congratulate all of you for organizing this fabulous event with involvement of eminent speakers and delegates.

We cordially invite you all, the researchers, regulatory authorities; standard-setting organizations; contract laboratories and research organizations, NGOs, academicians, scientists, students and healthcare practitioners of conventional and traditional health care systems and others who are interested in the dissemination of knowledge for the promotion and development of medicinal plants and natural products towards a healthier society to join SFE-India and explore the opportunities.

Prof. Pulok K Mukherjee, PhD, FRSC Secretary Society for Ethnopharmacology, India 23/3 Saktigarh, Jadavpur, Kolkata 700032 e-mail: [email protected] Please visit the website: www.ethnopharmacology.in

Dr. Pratim Banerji President Society for Ethnopharmacology, India 23/3 Saktigarh, Jadavpur, Kolkata 700032 e-mail: [email protected] Please visit the website: www.ethnopharmacology.in





National Seminar on “Ethnopharmacology : Perspectives for Development of Ayurveda”

NRIADD & SFE-INDIA, March 19, 2016

1

SPECIAL LECTURE SESSION

National Seminar, 2016

“Ethnopharmacology: Perspectives for Development of Ayurveda” NATIONAL RESEARCH INSTITUTE OF AYURVEDIC

DRUG DEVELOPMENT &

SOCIETY FOR ETHNOPHARMACOLOGY, INDIA

(SFE-INDIA)



2

Prof. V. K. Joshi

Born on January13,1953 in Almora, Uttarakhand. Obtained BAMMS from Lucknow University (1974); M.D.(Ay.) (1978) and Ph.D.(1984) from Banaras Hindu University. Served as Dean, Faculty of Ayurved IMS, BHU and serving as senior most Professor. Supervised- 8 Ph.D.; 21 M.D. (Ay.) Scholars and three each are working. Published, 75 scientific papers, in International / National Journals. At present, he is Chairman of the Ayurvedic Pharmacopeia Committee, Govt. of India, Ministry of AYUSH and Member of several committees of AYUSH, CCRAS, ICMR, CIMAP etc. He was nominated member of Govt. of India for; India – US Workshop (2016), Observer, HMPC, European Pharmacopoeia, London (2015), India-Africa Workshop (2011), “Consultation on Phytotherapy” Italy, WHO (2006), INDO-US Workshop, India (2003), World Intellectual Property Organization, Thailand (2000). Received, National Best Teacher Award (2002), International Zandu Oration award, (2016). Completed many projects like; “Field Survey of Traditional Medicinal Plants of Almora”, “Exploring functional genomics basis for medicinal properties (Dosha-balancing) of some plants used in Ayurveda” He wrote, “Benchmarks for training in Ayurveda”, which was published by WHO. Delivered 20 keynote addresses/ memorial oration, at National and International Conferences and Chaired/Co-Chaired more than 40 National and International Scientific Committees / Workshop and Conferences. Dr. S K Maulik

Dr. SK Maulik is presently a Professor in Pharmacology at All India Institute of Medical Sciences (AIIMS), New Delhi. He obtained his basic medical degree (MBBS) from Medical College, Calcutta, India and did his post graduation (MD, Pharmacology) and PhD from AIIMS. He has been actively involved in both basic and clinical Cardiovascular Pharmacology research for the last 27 years, as mentor of graduate students and principal investigators of six research projects, funded by government agencies. His basic research involves, cardiac ischemic reperfusion injury, pre-conditioning, cardiac hypertrophy, cardiac failure and pulmonary hypertension. His clinical research involves randomized clinical trials in patients of heart failure. His research interest also involves scientific validation of pharmacological effects of medicinal plants. He is a member of the editorial board of Experimental Cardiology, Indian Journal of Pharmacology, Experimental & Clinical Cardiology and associate editor of Institute of Integrative Omics and Applied Biotechnology (IIOAB) journal. He has published 52 original research articles in peer-reviewed international journals and contributed 15 chapters in several books.

SHORT BIOGRAPHY OF SPEAKERS



3

Dr. Debprasad Chattopadhyay

Debprasad Chattopadhyay, after obtaining Ph.D from Jadavpur University, and a brief post-doc training at London Hospital Medical College, joined ICMR. His work validated several ethnomedicinal practices of India, by establishing personal contact with the tribes. He has demonstrated the molecular mechanism of an antihistamine against antibiotic-resistant bacteria. Recently his group established the potent antiviral activity of an ethnomedicinal alkaloid, that block the immediate-early transcription of herpes virus with significant efficacy in animal model. His group also demonstrated the anti-typhoid activity of a medicament of Birhore and Santal tribes, against MDR Salmonella Typhi. He has 85+ peer reviewed publications including PLoS Pathogen, J Antimicrobial Chemotherapy, Antiviral Research, PLoS One, J Biological Chemistry, International J Antimicrobial Agents etc with reviews, books, and popular articles. He is the Fellow of the British Society for Antimicrobial Chemotherapy, and is associated with several International Journals and Universities as Reviewer, Examiner, visiting Faculty and Ph.D Guide.



4

ETHNO-PHARMACOLOGY IN AYURVEDA-THE TRADITIONAL INDIAN MEDICINE OF ANCIENT ORIGIN

Vinod Kumar Joshi

Professor of Dravyaguna, Faculty of Ayurveda, Institute of Medical Sciences, Banaras Hindu University, Varanasi-221005 Ethno-pharmacology deals with the knowledge of drug directly obtained from man. The search of new source of drugs for different ailments has definite relationship of man with plant source. A good number of modern drugs have their origin from the plants found in the nature and used by the man as folk-medicine. The knowledge of use of plant as drug in India is well recorded in Vedic compendia. Rigaveda (3000 BCE) and Atharvaveda (1500 BCE) are the compendium of Vedic tradition, where medicinal use of plants are ascribed. This knowledge continued and rational use of plants are well enumerated in origin scriptures of Ayurveda. In both the Samhitas, the knower of drugs is categorically ascribed along with name, morphological character and properties. Further, based on observation in animals first and thereafter their use in human beings was done. In fact, such observations were recorded in various geographical regions around the world. But, in India a systematic approach for its action was analyzed based on theory of Ayurveda. Not only that the action, the therapeutic based classifications are well recorded in original texts of Ayurveda. Thus based on repeated experiences, plants are broadly classified into non-poisonous, sub-poisonous and poisonous groups. Every plant has given a basonym with its synonymies, properties, action and therapeutic uses based on principles of pharmacology in Ayurveda. CLINICAL TRIALS OF AYURVEDIC DRUGS: NEED AND CHALLENGES

SK Maulik

All India Institute of Medical Sciences, New Delhi (on behalf of the Arjuna in Heart Failure Trial group) Integration of Indian system of medicine in the mainstream conventional system of medicine is the need of the hour. This is needed both for global recognition as well as better and affordable health care facilities at the grass root level in India. Instillation of scientific evidence in the century old system of medicine is an irrefutable requirement in fulfilling this challenging task and randomised clinical trial is a world-wide accepted tool for achieving such evidence base. In this context, we conducted a randomized double-blind placebo controlled clinical trial to assess the efficacy and safety of a standardized water extract of the stem bark of Terminalia Arjuna (an Ayurvedic drug) in 100 patients of functional class II heart failure on standard pharmacotherapy having LVEF ≤ 40%. They were recruited with informed consent and randomized 1:1 to Arjuna extract 750 mg or matching placebo twice daily. The primary outcome measure was change in LVEF at 12 weeks. Secondary outcome measures included changes in (i) NYHA functional class, (ii) distance covered in 6 minute walk test (6MWT), (iii) quality of life, as determined by the Kansas City Cardiomyopathy (KCCQ), (iv) plasma brain natriuretic peptide, (v) plasma cytokines and (vi) oxidative stress markers at 6 and 12 weeks. Safety

ABSTRACT OF SPEAKERS



5

assessment was done by adverse event monitoring and laboratory investigations. Results were expressed as mean ± SD or median (interquartile range) and analysed with intention-to- treat principle using appropriate two-sided statistical tests. A p-value < 0.05 was considered significant. Arjuna extract was well-tolerated, but did not change LVEF (24.3 ± 7.1 vs. 25.5 ± 7.7%; p=0.4) or secondary outcome measures. Significantly greater percentage increases occurred in distance covered in 6MWT, RBC-SOD, RBC catalase, RBC GSH and in symptom severity and stability domains of KCCQ in patients on Arjuna versus those on placebo, on a post-hoc analysis between subgroups of patients who improved in these outcomes. Although the Arjuna extract did not improve LVEF in CHF patients over 12 weeks, there was some increase in quality of life. The results provide a novel perspective in designing outcome in clinical trial with Ayurvedic drug in a chronic disease condition, like heart failure.



6

ORAL AND POSTER PRESENTATION

National Seminar, 2016

“Ethnopharmacology: Perspectives for Development of Ayurveda” NATIONAL RESEARCH INSTITUTE OF AYURVEDIC

DRUG DEVELOPMENT &

SOCIETY FOR ETHNOPHARMACOLOGY, INDIA

(SFE-INDIA)



7

SFE-INDIA/16/SEM/01 IDENTIFICATION OF CRUDE DRUGS AND THEIR COMMON SUBSTITUTES AND ADULTERANTS- A CASE STUDY OF KOLKATA MARKET Kshirod Kumar Ratha

1, Sreya Dutta2, Laxmidhar Barik1, Ashok Kumar Panda1, Debajyoti Das1, Achintya Mitra1, Rohit Kumar Ravte1, Sandip Dalui1, Jayaram Hazra1

National Research Institute of Ayurvedic Drug Development, CCRAS, Ministry of AYUSH, 4- CN Block, Sector-V, Bidhannagar, Kolkata, West Bengal. Medicinal plants play an important role in Ayurveda and other Traditional systems of medicine. Unintentional and intentional adulteration and substitution are commonly encountered in crude drug market of medicinal plants. Deforestation and extinction of many species and incorrect identification of many plants has resulted in adulteration and substitution of crude drugs. The trading of crude drug marketing practice in West Bengal mainly existed in two markets. viz; Kolkata and Siliguri Market. The wholesale medicinal plant market in Kolkata, covering 90% major trading units almost located within Burrabazar area in west-central zone of the city and roughly restricted within 1 km2. Many of them are deal with retail trading and bulk supply to the Ayurvedic pharmacies and only very few are engaging in export of medicinal plants. It is one of the important centers for medicinal plants collected from North east India and Nepal. Most of the items sold here by trade names, and not by their authentic names. To gather information about the types and source of crude drugs, three local traders were identified and interviewed. During the survey conducted during 2014-15, total 114 crude drug samples were collected and were identified macroscopically, and crosschecked with genuine samples of the institute. This study helps for identification of crude drug so that genuine material can be collected for manufacturing of Herbal medicine, and to maintain the genuineness and efficacy of the Herbal product. SFE-INDIA/16/SEM/02 THE TRADITIONAL KNOWLEDGE APPLICATIONS AND PHYTOCHEMICAL ANALYSIS OF CORDYCEPS SINENSIS (CLAVICIPITACEAE) OF BHUTAN

TH.Brojendro1, Laishram Decov Meitei

2,Th.Sobita Devi3

1Department of Chemistry, Oriental College, Imphal, Manipur, India 2Department of Chemistry, Himalayan University, Itanagar, Arunachal Pradesh, India 3D.M. College of Science (P.G. Section), Manipur, India Bhutan is a botanist paradise. Over 300 species of medicinal plants are reported from this mountainous region. Among the medicinal herbs, one species of mushroom known as Cordycep sinensis (Clavicipitaceae) is well known for its high potential medicinal value. The fruiting body and attached mycelium of cordyceps have been used in Chinese traditional medicine for centuries.Cordycepin is found to be the main functional component in Cordyceps.Like TCM practitioners,indigineous people in Bhutan also used Cordyceps to strengthen resistance against infectious diseases,curing chronic diseases and generally in improving the homeostasis of the long suffered patient.Cordyceps is also valued for its activity in restoring energy,promoting longevity and improving quality of life.Fermented Mycelia are produced on a large scale and has become better source of medicine.So the phytochemical screening of this medicinal plant has been made by the help of Atomic Spectroscopic technique.The preliminary phytochemical screening indicates the presence of alkaloids, saponins, tannins, flavinoids and steroids.Trace elements like Cu, Zn, Cr, Fe and Mn. The same species is reported for Indian states like Sikkim and Himachal Pradesh.The folk healers of Sikkim and Bhutan use C.Sinennsis to cure 21 ailmemts including cancer, asthma,TB, diabeties, cough and cold

ORAL PRESENTATION



8

erectile dysfunction in male and female , hepatitis etc. Many studies in vitro and in vivo support C.Sinensis having diverse biological activities and pharmacological potential. Available evidence regarding C.Sinensis’s medicinal value seems to be very promising, but there is a lack of study performed specifically on humans and in ayurvedic drug designing.More mechanism-based and disease oriented pharmacological studies should be iniated and encouraged.To undertake detailed pharmacological studies of C.Sinensis for its pharmacokinetics,pharmacodynamics, and toxicities in humans is the need of the hour. In Ayurvedic pharmacopoeia, C.Sinensis may fall under Rasayana category. The finding will help in new drug discovery of modern therapy and modern ayurvedic drug designing. SFE-INDIA/16/SEM/03 ANTIBACTERIAL ACTIVITY OF POLYPHENOLS FROM KOMBUCHA AND MODE OF ACTION AGAINST ENTERIC PATHOGENS Debanjana Bhattacharya

1, Semantee Bhattacharya1, Ratan Gachhui1

1Department of Life Science & Biotechnology, Jadavpur University, 188, Raja S.C. Mullick Road, Kolkata, India Kombucha is a popular traditional medicine and consumed in different parts of the world due to its various claimed and a few established pharmacological effects. It is prepared by fermenting sugared black tea with a consortium of acetic acid bacteria and yeasts for 14 days at 28°C. In the present article we focussed on the inhibitory activity of Kombucha against common enteropathogens viz. enterotoxigenic Escherichia coli (ETEC) 157:H7, Vibrio cholerae N16961, Shigella flexneri 2a 2457T, Salmonella Typhimurium NCT 572 with identification of its active constituents and investigation of the mode of action. Successive extraction of Kombucha by chloroform, ethyl acetate and n-butanol and bioactivity-guided screening led to the isolation of ethyl acetate extract which showed maximum antibacterial activity. The ethyl acetate extract was further fractionated by thin layer chromatography and one of its fractions exhibited strongest inhibition. This active fraction contained the polyphenols catechin and isorhamnetin as detected by Mass spectrometry and RP-HPLC analysis. Isorhamnetin exhibited major antibacterial spectrum against the test strains. Furthermore, isorhamnetin was found to disintegrate bacterial cytoplasmic membranes with the leakage of nucleotides and proteins in both time-dependent and concentration-dependent manners. Hence our results suggest the fact that Kombucha could be exploited as an alternative source of various polyphenols in treating enteric bacterial infections. SFE-INDIA/16/SEM/15 ROLE OF CHATURBEEJA CHURNA IN SPASMODIC DYSMENORRHOEA (KASHTARTAVA): A CLINICAL STUDY

Neha Mishra1 1Dept of Kaya Chikitsa, IPGAE&R AT SVSP, 294/3/1, APC Road, Kolkata, India

In modern era, the most common gynaecological complain reported is spasmodic dysmenorrhoea, where there is pain during menstruation without any pelvic pathology. In Ayurveda, KASHTARTAVA, is the term which is used to denote such condition. Chaturbeeja churna has an effective role for pacifying such condition as it relieves the pain. The study was conducted in a group of 10 female patients aged between 12 to 40 yrs by prescribing chaturbeeja churna i.e following drug powder in equal ratio METHIKA – Trigonella foenumgraceum Linn; CANDRASHURA – Lepidium sativum Linn.; KALAJAJI- Nigella sativa Linn.; YAVANIKA – Trachyspermum ammi Linn. The dose was 3gm twice daily with lukewarm water for 10 days (7 days before onset of menstruation till third day of the bleeding phase). After following the proper course of medicine it was seen that out of 10 patients, 4 were markedly improved, 3 were moderately improved and 2 were improved. The main cause of Kashtartava, according to Ayurved, is due to vitiation of Vata dosa. Due to ushna virya, a vata kapha nashaka and snigdha property, the churna is effective in such conditions.



9

SFE-INDIA/16/SEM/20 FUNDAMENTALS OF PHARMACOLOGY IN PRESENT DAY AYURVEDA Nilanjan Datta

1 , Phalgun Roy1

1PGT , IPGAE &R, SVSP hospital, Kolkata, India Ayurveda looks at the pharmacological properties of medicinal dravyas (drugs). The action of substances were explored in terms of Rasa, Guna,Veerya Vipaka and Prabhava.The subject that deals with this matter is called dravyaguna. Ayurvedic pharmacology deals dravyas and how they make use of their effects. There is a difference between what a dravya does and how it acts. For eg. Bacopa is known to enhance memory and G.glabra promotes the healing of duodenal ulcers. As per Ayurveda they are Medhya (promotes intellect) and Vranaropak (ulcer healing) respectively. Ancient ayurvedic scholars used to explain MOA of these dravyas in the context of above mentioned properties.We have seen some Dravyas is having multifold action, for e.g. Shatavari is having lactogenic, adaptogenic and ulcer healing property. But question arises how a same herb exert different activities.That can be well explained on the basis of fundamental understanding of medicines. Ayurvedic scholars explain that some properties are concerned with the Rasa, some with Guna etc.Today we came to know that drugs have multiple phytochemicals to carry out such actions.

SFE-INDIA/16/SEM/28 ENHANCEMENT OF SOLUBILITY, BIOAVAILABILITY AND HEPATOPROTECTIVE EFFICACY EVALUATION OF BETULINIC ACID THROUGH NANOEMULSION AS A NOVEL CARRIER SYSTEM Ranjit K Harwansh

1, Pulok K Mukherjee1, Rajarshi Biswas1, Sayan Biswas1

1School of Natural Product Studies, Department of Pharmaceutical Technology, Jadavpur University, Kolkata, India Betulinic acid (BA) is a potent phytomolecule obtained from plant kingdom and has proven for its antioxidant and hepatoprotective activity. However its efficacy is restricted due to poor solubility as well as poor bioavailability. The aim of this study was to develop a BA loaded nanoemulsions (NEs) to overcome these limitations and to investigate the impact of the nanoemulsion on hepatoprotective efficacy and bioavailability. The nanoemulsion (BA-NE1) was prepared with of olive oil (oil phase), aqueous system and surfactant (labrasol) and co-surfactant (plurol isostearate) [Smix] in an optimized ratio of 20:25:55 % w/w respectively. BA-NE1 was prepared by spontaneous nano-emulsification method. The BA-NE1 was assessed through different parameters including droplet size, zeta potential, refractive index, TEM, UV-spectrophotometry, FTIR and stability study. Among five different nanoemulsion formulation, the best average droplet size (150.3 ± 0.56 nm) and zeta potential (-10.2 ± 0.11 mV) were observed with BA-NE1. The improved relative bioavailability (440.48 %F) and pharmacokinetics including Cmax (96.29 ± 1.96 ngmL-1), AUC0-t∞ (2540.35 ± 278.31 nghmL-1) Tmax (12.32 ± 0.05 h) and elimination half-life (11.35 ± 3.20 h) was significantly achieved with BA-NE1 as compared to pure BA for longer periods. The BA-NE1 significantly restored the levels of serum hepatic marker enzymes and hepatic antioxidant enzymes with respect to CCl4-intoxicated groups (P < 0.05 and P < 0.01). Therefore, the current study suggests that BA loaded NE has enhanced the hepatoprotective activity of by increasing their solubility and improving the bioavailability.



10

SFE-INDIA/16/SEM/29 MUSHROOM TYROSINASE INHIBITORY MECHANISM OF BETULINIC ACID: ISOLATED FROM FRUIT OF DILLENIA INDICA Rajarshi Biswas

1, Pulok mukherjee1 , Ranjit K Harwansh1, Joydeb Chanda1, Amit Kar1, Debayan Goswami1, Sayan Biswas1, Subhadip Banerjee1, Akansha Sharma1, Mrinmoy Nag1, Shiv Bahadur1.

1School of Natural Product Studies, Department of Pharmaceutical Technology, Jadavpur University, Kolkata, India Elephant apple is the fruit of Dillenia indica L. widely grown in tropical forests of India. The fruits of D. indica are used as traditional skin lighting preparation in India. The aim of the study was explored the tyrosinase inhibitory mechanism of betulinic acid from D. indica. Extraction was carried out with methanol and anti-tyrosinase assay guided isolation was performed by using flash chromatography. RP-HPLC analysis of the bio-active fractions was performed simultaneously. Diphenolase activity of tyrosinase was investigated by nonlinear regression analysis of enzyme kinetic data. Moreover, ANS-binding fluorescence assay, circular dichroism (CD) spectroscopic analysis and molecular docking study were performed to elucidate the mechanism of binding of the inhibitor with tyrosinase. Bio-activity guided fractionation, and RP-HPLC analysis explored that the betulinic acid was responsible for tyrosinase inhibition. The IC50 value of betulinic acid was found to be 5.08 ± 2.01 µM for diphenolase inhibition activity of tyrosinase. From enzyme kinetic analysis, mixed non-competitive inhibition on tyrosinase was confirmed. ANS-binding fluorescence measurement and CD spectroscopy analysis showed that betulinic acid did not induce drastic changes in tertiary and secondary structure of tyrosinase. Further, results of molecular docking algorithms showed that the betulinic acid can interact with amino acid residues outside the tyrosinase active site. Thus, betulinic acid from D. indica may be useful in preventing enzymatic browning reactions of food product and hyperpigmentation syndrome in human skin.



11

SFE-INDIA/16/SEM/04 FORMULATION AND DEVELOPMENT OF ALGINATE CHITOSAN ENCOATED OMPA MICROPARTICLE- A SHIGELLA PROTEIN SUBUNIT VACCINE AGAINST SHIGELLOSIS Priyadarshini Mukherjee

1 , Dhrubajyoti Nag1, Ritam Sinha1, Manoj K. Chakrabarti2, Hemanta Koley1

1Division of Bacteriology, National Institute of Cholera and Enteric Diseases, P-33, CIT Road, Scheme XM, Beliaghata, Kolkata, India. 2Division of Pathophysiology, National Institute of Cholera and Enteric Diseases, P-33, CIT Road, Scheme XM, Beliaghata, Kolkata, India. Shigellosis or bacillary dysentery, caused by Shigella sp, remains as an important public health problem in developing as well as developed countries. Though Shigella was discovered century ago till date no licensed vaccine is available for public use. Antibiotics are the only choice for the treatment of shigellosis. But the irrational use of antibiotics leads to emergence of multidrug resistant bacteria. Thus vaccine is the only way to prevent shigellosis. Shigella encompasses four subgroups (S. flexneri, S. sonnei, S. dysenteriae and S. boydii) based on the structure of the O-antigen repeats that comprise the polysaccharide moiety of the lipopolysaccharide. Thus an ideal Shigella vaccine must confer protection against not only single serotype but all serogroups. In this present study, mucoadhesive chitosan alginate microparticles were investigated as a new vehicle for delivery of OmpA protein. OmpA protein an efficacious immunogen is embedded in the outer membrane of Shigella as a beta barrel protein highly conserved among all Shigella sp. We expressed and purified recombinant his-tag OmpA protein and coated with chitosan-alginate microparticle(CAOP). Chitosan-alginate microparticles were prepared by ionotropic gelation method and characterization of microparticles was investigated by TEM and DLS technique. The mean diameter of the microparticles was about 550nm. In our experimental animal model, oral immunization of mice with the CAOP induces strong protective immunity against the lethal challenges with different prevalent serogroups of Shigellae. Hence OmpA coated with chitosan-alginate microparticles (which act as a delivery system) is a promising novel candidate vaccine against human shigellosis. SFE-INDIA/16/SEM/05 EVALUATION OF THE EFFICACY OF VAITHARANA BASTI AND ERANDAMOOLADI NIROOHA BASTI IN GRIDHRASI W.S.R. TO SCIATICA Surabhi Dey

1, Sayantan Bera1, Ramkrishna Patra1, Tapas Kr. Mandal1, Rupa Mukherjee1.

1Department of Panchakarma, Rajib Gandhi Memorial Ayurvedic College and Hospital, Kolkata, India Gridhrasi comes under 80 types of Nanatmaja Vatavyadhi The cardinal signs and symptoms of Gridhrasi (Sciatica) are Ruka (pain), Toda (pricking sensation), Stambha (stiffness) and Suptata (twitching) in the Sphika, Kati, Uru, Janu, Jangha and Pada in order and Sakthikshepa Nigraha i.e. restricted lifting of the leg. In Kaphanubandha, Tandra, Gaurva, Arochaka are present. Low backache is a prevalent Universal health problem and the Gridhrasi is realized to be a major cause of this pain. Basti can be of many types on the basis of ingredients and needs.In presents study continuous Vaitharana Basti for 8 days and Erandamooladi Nirooha in Yoga Basti karma is selected, Moorchita Tila Taila are used in Both Basti. In the present study, minimum of 30 diagnosed gridhrasi (sciatica) patients are selected to assess. A Simple comparative clinical Prospective study and sampling technique is purposive or deliberate. A minimum of 30 patients suffering from Gridhrasi are selected in 2 groups, 15 patients in each group. Group A- 15

POSTER PRESENTATION



12

patients was received Vaithrana Basti continuous for 8 days by using Surbhi payas. Group B-15 patients was received Erandamooladi Nirooha Basti and Moorchita Tila taila anuvasana Basti in Yog Basti krama. Result are drawn on collective effects of therapy on Subjective and Objective parameters. Amonga 30 treated patients 2(6.66%) patients good responsed, 24 (80%) patients moderate responsed, 4 (13.33) patients mild responsed and 2 (6.66) patients not responsed to the treatment. SFE-INDIA/16/SEM/06 COMPARATIVE CLINICAL EVALUATION OF THE EFFICACY OF SHIRODHARA IN ESSENTIAL HYPERTENSION Subhasis Bera1

, Sarmistha Kundu1, Sayantan Bera1, Ramkrishna Patra1, Srabani Das1, Rupa Mukhopadhyay1

1Department of Panchakarma, Department of Kayachikitsa, Rajib Gandhi Memorial Ayurvedic College and Hospital, Kolkata, India Ayurveda describes hypertension in parlance with Pittavrita vata. The signs and symptoms like Shira Shoola, Bhrama, Tama, Daha which are similar to the clinical features of essential hypertension viz headache, dizziness, easy fatigability, elevated blood pressure etc. Shirodhara is a specialised procedure of Panchakarma known as Bahya snehana in the form of external oleation therapy in which a stream of any of the medicated material like Taila, Kwatha, Dugdha, Takra etc, are poured over forehead for specific period in a streamline and rhythmic flow as per the disease. A simple Randomized Comparative Clinical Prospective Trial was undertaken with 30 patients from O.P.D and I.P.D. Department of Panchakarma were assigned into two groups each having 15 patients. In group A, 15 patients were subjected to Shirodhara with Laghupanchamula kwatha whereas in group B: 15 patients were treated with Shirodhara with Yastimadhu ksheera. Blood Pressure recorded on supine and sitting positions were taken as objective parameters. The present study revealed that in group A the effect on Systolic Blood Pressure was 2.60 (S.D. 0.632) before treatment is reduced to 2.07 (S.D. 0.458) after treatment and after the follow-up is reduced to 2.00 (S.D. 0.378). In group-B, before treatment was 2.27 with S.D. 0.458 is reduced to 2.20 (S.D. 0.458) after treatment and after the follow-up is reduced to 2.13 with S.D. 0.352. The parameter ‘Systolic Blood Pressure.’ shows significant in group-A as P<0.05, BT to AT and BT to AF. The parameter ‘Diastolic Blood Pressure.’ showed no significant change within two groups Over all we observe that Group B treatment performed significantly well on all the parameters. SFE-INDIA/16/SEM/07 EVALUATION OF THE EFFICACY OF VAITARANABASTI IN AMAVATA W.S.R TO RHEUMATOID ARTHIRITIS. Madhumita Das1

, Sayantan Bera1, RamkrishnaPatra1, Tapas Kr. Mandal1, Rupa Mukherjee1.

1Department of Panchakarma, Department of Kayachikitsa, Rajib Gandhi Memorial Ayurvedic College and Hospital, Kolkata, India

In Ayurveda chikitsa is broadly classified into two parts shodhana and shamana. Here also shodhana occupies first place. Among five shodhana procedures Vastiis one among them and it has been called as Ardhachikhtsa.Amavata whichis correlative to rheumatoid arthiritis is common among chronic inflammatory joint diseases in which jointsbecome swollen, painful, and stiff. Therefore, the Amapachana, Lekhana,Vatanulomana etc, be used to treat this disease. Vaitaranabasti is prime treatment for Amavata in turn plays vital role in correcting pathology of the disease andgives remarkable results. A simple Randomized Comparative Clinical Prospective Trial was undertaken with 30 patients from O.P.D and I.P.D. Department of Panchakarma. Out of 30 patients, 15 patients (i.e.50%) were got good response, 14 (46.66%) patients were got moderate response, 1 patient (i.e.3.33%) was not responded to the treatment inDAS criteria. In Extra Articular Manifestation of Ritchie Articular Index(EAMRIA): scale among 30 patients 9 patients have got more than 75% improvement,3 patientshave got 50% improvement, and other 18 patients have not got any improvement.Ritchie Articular Index (RIA) showed 24 patients have got more than 75% improvement, 5 patientshave got 50% improvement, and 1 patient have got below 25% improvement.VAS (Assessment of pain)



13

showd that 18 patients have got50% improvement, 12 patients have got more than 25% improvement. Thus the treatment of vaitaranabasti in Amvata or rheumatoid arthiritis could be suitable treatment with significant reduction in clinical symptoms which need further exploration. SFE-INDIA/16/SEM/08 COMPARATIVE STUDY TO EVALUATE THE EFFECT OF TWO DIFFERENT VIRECHANA YOGA IN MADHUMEHA (NIDDM). Madhuchhanda Das

1, Sayantan Bera1, Sonali Mukherjee1, Ramkrishna Patra1, Rupa Mukherjee1.

1Department of Panchakarma, Department of Drvyaguna, Rajib Gandhi Memorial Ayurvedic College and Hospital, Kolkata, India Madhumeha mentioned in Ayurveda can be compared with NIDDM. Type II diabetes, a multifaceted disease, manifested by hyperglycemia that result from several deregulated biological mechanisms. In the patients of Madhumeha, the Kapha and Pitta are vitiated excessively and they remain lying in the lower part of the body. Whereas, Virechana has the quality to eliminate both Pitta and Kapha, also it is the best Shodhana therapy for the elimination of Dosha situated in the lower parts of the body. The research was aimed to know the efficacy of Virechana in reduction in signs and symptoms, effect on Blood Glucose Level. Patients (n = 30) suffering from symptoms of Madhumeha of NIDDM were selected from O.P.D. of the hospital. Objective paramters like fasting blood sugar (FBS), postprandial blood sugar (PNS), fasting urine sugar (FUS), postprandial urine sugar (PUS) were considered for all the patients. Group A patients received Kalyanaka Guda and Vidanga Tanduladi Choorna was given in group B. FBS in Group-A before treatment mean was 2.13 and after follow up mean was 1.26 and percentage of relief 87.7%, which was highly significant at the level of P<0.01 whereas in PBS in Group-A- before treatment mean was 2.2 and after follow up mean was 1.66 and percentage of relief 87%, which was highly significant at the level of P = 0.014. In Group-B- before treatment mean was 2.33 and after follow up mean was 2.53 and percentage of relief 7.9 %, which was highly significant at the level of P>0.05. In Overall, Among 30 patients, 4 patients (13.33%) got Good Response, while 18 patients (60.00%) got Moderate Response, 7 patients (23.33%) got Mild Response, and 1 patient (3.33%) showed Poor Response. Thus Group A shows better effect than Group B. SFE-INDIA/16/SEM/09 CLINICAL STUDY ON EFFECT OF PINDA SWEDA IN JANUSANDHIGATAVATA W.S.R TO KNEE JOINT OSTEOARTHRITIS Arpita Nandi

1, Sayantan Bera1, Sonali Mukherjee1, Ramkrishna Patra1, Srabani Das1, Rupa Mukherjee1.

1Department of Panchakarma, Department of Drvyaguna, Department of Roga Vijnana & Vikriti Vijnana Rajib Gandhi Memorial Ayurvedic College and Hospital.

Sandhigatavata is a type of Vatavyadhi which may be correlated with Osteoarthritis. Pinda sweda, a type of Sankara sweda is effective in the management of vitiated Vata dosha. It helps in relieving the cardinal symptoms of Janusandhigatavata like Janusandhi shoola, shotha and prasarana aakunchana pravrutti savedana. It was a simple comparative prospective clinical trial. The study was done in two groups; Group A and Group B having 15 patients each. Duration of treatment was 7 days Patients of Group A received Shastika shali pinda sweda, in aarohana karma (starting with 15 minutes on first day, increasing 5 minutes everyday upto 30 minutes on fourth day and then reducing 5 minutes everyday upto seventh day). Patients of Group B received Patra pinda sweda in similar fashion for seven days. Both Group A (Shastika shali pinda sweda) and Group B (Patra pinda sweda) showed statistically significant change in subjective and objective parameters. Comparatively, Group A showed better improvement in Janusandhi shoola, sparsha akshamatva, sandhigati asamarthata, shotha than Group B. Group B showed better improvement in Janusandhi stambha than Group A. Whereas both groups showed almost same improvement in the parameters of WOMAC and VAS. The study revealed, Shastika shali pinda sweda is more effective than Patra pinda sweda in the



14

management of Janusandhigatavata. The present trial could contribute a moderate relief (50-74% relief) in 23.33% of the patients, a Mild Improvement (>25-49% relief) in 70% of the patients, Poor response (<25% relief) in 6.66% of the patients. SFE-INDIA/16/SEM/10 EVALUATION OF CYTOPROTECTIVE ACTIVITY OF SYZYGIUM SAMARANGENSE USING IN-VITRO AND EX-VIVO MODELS ON OXIDATIVE STRESS AND INFLAMMATION Soumen Dhara

1, Asis Bala1, Prerona Saha1

1Guru Nanak Institute of Pharmaceutical Science and Technology, 157/F, Nilgunj Road, Panihati, Kolkata, India The aim of this study to identify and isolate the molecule of leaf extract of Syzygium Samarangense (Family-Myrtaceae) by in-vitro and ex-vivo models on oxidative stress and inflammation. Identified plant were dried and extracted by soxhlet extraction procedures using ethanol. Different qualitative and quantitative studies were performed to estimate total phenolic content (TPC) and total flavonoid content (TFC). In-vitro anti-oxidant activity was done by some of biochemical methods to estimate nitric oxide and hydrogen peroxide scavenging activity. Additionally ex-vivo studies were performed on human Red Blood Cells (hRBC) to confirm its antioxidant and anti-inflammatory activity. Percentage yield of leaf extract was 9.155 % w/w. Presence of alkaloid and flavonoid were confirmed in the extract by phytochemical test. TPC was found to be 41.17± 5.490 (Eq. to Gallic acid) µg/mg and TFC was found to be 13.37± 0.4985 µg/mg. Concentration dependent % inhibition was observed in the entire biochemical assay on assessing of free radicals scavenging. However the IC50 value of nitrite-induced lysis of hRBC was 83.117 µg/ml. Further study can be carried out to identify the active compounds which might be responsible for this anti-oxidant and anti-inflammatory activity. SFE-INDIA/16/SEM/11 IDENTIFICATION AND QUANTIFICATION OF PIPERINE IN DIFFERENT AYURVEDIC POLYHERBAL FORMULATIONS BY HPTLC TECHNIQUE Banti Chakraborty

1, Alok K. Hazra1, Soumya Mondal1, Achintya Mitra2, Tapas K. Sur3

1Ramakrishna Mission Ashrama, Quality Testing Laboratory, Narendrapur, Kolkata 2National Research Institute of Ayurvedic Drug Development, Salt Lake, Kolkata 3Department of Pharmacology, I.P.G.M.E & R, Kolkata Ayurvedic churna (powder) formulations such as Trikatu, Sitopaladi, Hingastak, Avipattikar, Sringadi and Talisadi are the most common that are traditionally used from ancient times to treat asthma, cough and cold, tuberculosis, indigestion, chronic rhinitis/sinusitis and other respiratory disorders. Interestingly, in has been noted that in all these formulations one or more herbal ingredients have origin from the genus Piperaceae, like Piper longum (pipul), Piper nigrum (marich), Piper chaba (chai), Piper cubeba (kabab chini) etc. The presence of piperine, an alkaloid (C17H19NO3) is an active principle in this group of herbs. Modern research confirmed that piperine exhibits a variety of biological actions including, anti-inflammatory, anti-asthmatic, antioxidant, anti-hypertensive, anti-platelet, anti-tumor, anti-pyretic, hepatoprotective, bio-enhancer etc. Although these powder formulations are very popular Ayurvedic medicines, unfortunately these lack establishment of quality control issues. Hence, the aim of this study was to establish a QC tool for efficacy and consequently a simple validated HPTLC method has been developed for the estimation of piperine in Ayurvedic formulations (churnas) that contain herbs from Piperaceae family. Extraction containing Piperine was performed from the above 6 churnas and 4 herbs and HPTLC was done using Piperine as standard. The mobile phase was a mixture of toluene-ethyl acetate (7:3, v/v) and detection at 342 nm. It was observed that Piper nigrum is a rich source of Piperine compared to other plants and the formulations containing marich also have substantial piperine content. The results are helpful to physicians, clinicians and pharmacists to draw significant role of piperine present in all these samples.



15

SFE-INDIA/16/SEM/12 STUDY OF NEURO-PROTECTIVE ACTIVITY OF ASHWAGANDHA AND VACHA IN COMBINATION AS AYURVEDIC MEDHYA RASAYANA IN -VIVO Chandreyee Ray

1, Parikshit Debnath1, Achintya Mitra2,Rohit Kumar Ravte2 , Jayram Hazra3, Mradu Gupta4

1 Senior Research Fellow (Ayu), National Research Institute of Ayurvedic Drug Development, Kolkata 2 Research Officer (Ayu), National Research Institute of Ayurvedic Drug Development, Kolkata 3 Director, National Research Institute of Ayurvedic Drug Development, Kolkata 4 Professor and Head, Department of Dravyaguna Vijnan, Institute of Post Graduate Ayurvedic Education & Research at SVSP Hospital, Kolkata To evaluate Neuroprotective activity in-vivo with Ashwagandha (Withania somnifera Dunal) & Vacha (Acorus calamus Linn.) formulated in w/w 2:1. In-vivo models using Wister Rats and Swiss Mice were assessed with Conditioned Avoidance Response Test (CART) (6 groups; n=6 rats in each) and Eddy’s Hot Plate Analgesiometer (4 groups; n=6 mice in each group). In 3 groups Electro convulsive shock (ECS) was given. Initially drug-dose standardization was done by comparing 500 mg/kg and 700 mg/kg body weight. The standard test drug dose was taken as 700 mg/kg body weight. The retention of CART after drug administration and ECS was calculated on 9th day. The rats in test drug group showed significant increase in retention of CART as compared to Control (normal saline) (p<0.001). ECS+ test drug significantly prevented the ECS induced attenuation of CART (p<0.001). Hot Plate analgesiometer showed significant (p<0.001) increase in latency period compared to standard drug (Fortwin 0.5 mg/kg i.p) observed at 90 min. The central analgesic effect of the research drug at the 700 mg/ kg was highly significant (p<0.001) in comparison to control group at 60 and 90 min interval pointing out the analgesic effect being sustained. The present study with standardized aqueous extract of Ashwagandha and Vacha produced significant increase in pain threshold time compared to control and standard drug. Conclusions: The neuro-protective action of the formulation was established in experimental model. Randomized Clinical Trials should be done in the future to be more conclusive about the efficacy of the nootropic formulation. SFE-INDIA/16/SEM/13 EVALUATION OF THE EFFECT OF GSH (R) ON L-ARGININE AND 5-FU CO-CULTURED EHRLICS ASCITES CARCINOMA (EAC) CELLS Lopamudra Roy

1, Asis Bala1, Abhijit Sengupta1

1Division of Pharmacology, Guru Nanak Institute of Pharmaceutical Science and Technology, Kolkata,India. To observe the effect of 5-FU on Ehrlich’s Ascites Carcinoma (EAC) cell line as well as standardization of concentration of L-Arginine (L-Arg.) having highest synergistic effect in combination with 5-FU on EAC cell line on short time incubation. Moreover the effect of different concentration of 5-FU with standard concentration of L-Arg on EAC cell line in short term incubation has also been observed. The EAC cells were maintained in vivo in Swiss albino mice by intra-peritoneal transplantation of 2×106 cells per mouse after every 10 days. Freshly collected EAC cells were treated with different concentration of 5FU to get the effective 5FU concentration and that 5FU concentration was treated with different GSH & L-Arginine concentration to check the viable and non-viable cell count under microscope using trypan blue and the most effective L-Arg concentration is taken to check the effectivity of GSH in combination with 5FU and L-Arginine. IC50 value was found to be 109.5±1.67 µg/ml for 5FU, however this value was decreased 73.58±2.16 when the cell were incubated with L-Arg with 5FU due to synergistic action. As per our hypothesis whenever the cells were incubated with GSH as well as L-Arg and 5FU, synergism lost and the IC50 value again increased and it was found to be 95.88± 0.525. Taken together we can conclude that GSH decreased the synergistic effect of L-Arg and 5FU probably due to its antioxidant effect as the peroxinitrite is the active key molecule for the synergism.



16

SFE-INDIA/16/SEM/14 IDENTIFICATION OF CYTOTOXIC FRACTIONS OF ARECA CATECHU NUT ON EHRLICH’S ASCITES CARCINOMA CELLS USING IN VITRO ASSAY Senjuti Mukherjee

1, Asis Bala1, Sumana Chatterjee1

1Guru Nanak Institute Of Pharmaceutical Science And Technology, 157/F, Nilgunj Road, Sodepur, Panihati, Kolkata, Pin-700114 Areca nut, commonly called as betel nut or supari, is a fruit of areca catechu palm tree, which is native of South Asia and Pacific Islands, and Western Ghats, Eastern Ghats, subtropical area in India. Chewing areca nut is thought to have central nervous system stimulating effect and along with this it is known to have salivary stimulating and digestive. Along with just using it as a chewing agent with piper bettle leaves it also has certain pharmacological activities such as Antioxidant, Anti-inflammatory, Antihelminthic, Antisaporadiac, prevents Halitosis, and others. The cytotoxic activity of Areca is being studied and observed on Ehrlich’s Ascites carcinoma cell lines. Fresh areca nuts were powdered after drying in a mechanical grinder and ethanolic extraction was carried out using soxhlation. In vitro cytotoxic activity of the ethanolic extract was evaluated on Ehrlich’s Ascites Carcinoma and the cell viability was confirmed by trypan blue assay. After the initial confirmation of cytotoxicty, the crude extract was further fractioned. Further studies were done on both crude extract and on alkaloid fraction. The mean IC50 values for crude ethanolic extract of areca and alkaloid fraction were found to be 37.90±3.790µg/ml and 63.28±2.422µg/ml respectively. SFE-INDIA/16/SEM/16 SELECTIVE INHIBITION OF LEISHMANIA DONOVANI BY SEMI-PURIFIED FRACTION OF WILD MUSHROOM GRIFOLA FRONDOSA

Sirin Salma Sultana

Narayan Ghorai1, Joydip Ghosh1, Sondipon Chakraborty2, Debarati Mukherjee1, Somaditya Dey1, Soumitra Paloic3,

Somanjana Khatua3, Tanmoy Dutta4, Soumen Bhattacharya4, Krishnendu Acharya3, 2, Chiranjib Pal1

1Cellular Immunology and Experimental Therapeutics Laboratory, Department of Zoology, West Bengal State University, Barasat, West Bengal, India 2Wildlife Biology and Natural Product Research Laboratory, Department of Zoology, West Bengal State University, Barasat, West Bengal, India 3Molecular and Applied Mycology and Plant Pathology Laboratory, Department of Botany, University of Calcutta, West Bengal, India 4Department of Zoology, University of North Bengal, Darjeeling, West Bengal, India

Leishmania is the ninth largest infectious disease and is highly endemic in the Indian subcontinent and East Africa. An estimated 200000 to 400000 new cases of VL occur worldwide each year. Over 90% of new cases occur in 6 countries: India, Nepal, Bangladesh, Brazil, Ethiopia, and Sudan. A very limited approach has been made till date to establish the mushrooms or mushroom derived metabolites as therapeutic agent against Leishmania infection. As few as only eight reports, including four from our group, have been documented regarding the anti-leishmanial effect of extracts or active constituents of wild mushrooms till 2015. In continuation with our line of investigations on anti-leishmanial leads, we claimed that a semi-purified fraction (designated as GFa) of wild mushroom Grifola frondosa significantly inhibited the survival of three different species of Leishmania parasite (L. donovani, L. tropica & L. major) in vitro. The semi-purified fraction of Grifola frondosa (IC50: 20 µg/ml) was found more effective against Leishmania donovani promastigotes in comparison to crude extract of Grifola frondosa (IC50: 100 µg/ml). GFa interfered in cell cycle progression, lipid biosynthesis, altering the morphology and inducing the apoptosis in promastigotes. More interestingly, the 50% inhibitory concentration of GFa was estimated much lower against the intracellular amastigotes (IC50: 2.5 µg/mL), the pathogenic form of the parasite in mammalian host in comparison to promastigotes (IC50: 20

javascript:;�



17

µg/ml) and induced the pro-inflammatory cytokines in infected macrophages. GFa was also found noticeably non-toxic towards murine splenocytes. Gas-chromatography analysis revealed that 1,2-Benzenedicarboxylic acid, bis(2-methylpropyl) ester, 1,2-Benzenedicarboxylic acid, butyl 2-methylpropyl ester, 1,2-Benzenedicarboxylic acid, dibutyl ester, Phthalic acid, isobutyl 2-Pentyl ester, Pathalic acid ,butyl 2-Pentyl ester, Pathalic acid, butyl 2-ethyl hexyl ester are the primary constituents of active semi-purified fraction of Grifola frondosa. The findings of the present study established that the constituents of G. frondosa might be an interesting lead for the exploration of anti-leishmanial molecules. SFE-INDIA/16/SEM/17 ASTRAKURKURONE, A NOVEL TRITERPENE ISOLATED FROM INDIAN MUSHROOM ASTRAEUS HYGROMETRICUS, INDUCES MITOCHONDRIAL DYSFUNCTION AND REACTIVE OXYGEN SPECIES DEPENDENT DEATH IN LEISHMANIA DONOVANI Suvadip Mallick1, Somaditya Dey

1, Supratim Mandal1, Aritri Dutta1, Debarati Mukherjee1, Gunjan Biswas2, Soumya Chatterjee2, Sanjaya Mallick3, Tapan Kumar Lai4, Krishnendu Acharya2, Chiranjib Pal1

1Cellular Immunology and Experimental Therapeutics Laboratory, Department of Zoology, West Bengal State University, Barasat, West Bengal, India 2Molecular and Applied Mycology and Plant Pathology Laboratory, Department of Botany, University of Calcutta, West Bengal, India 3CU BD Centre of Excellence for Nanobiotechnology, University of Calcutta 4Department of Chemistry, Vidyasagar Evening College, Kolkata, West Bengal, India. There is an urgent need for searching efficient, target specific antileishmanial molecule from indigenous natural resources to add in the pool of drug discovery against L. donovani as the current chemotherapeutics have been proven not to be so prudent due to emergence of resistance and severe toxicity. Interestingly, the 50% inhibitory concentration of astrakurkurone could induce apoptosis as evidenced by the externalization of phosphatidyl serine, hoechst+ and TUNEL+ promastigotes. The time dependent elevation of astrakurkurone-induced reactive oxygen species (ROS) was found intimately associated with apoptosis. The preincubation of promastigotes with one of the protease inhibitors, trypsin inhibitor, pan caspase inhibitor, Ca2+ chelator, non selective cation channel blocker did not have any effect on parasite killing, whereas the ROS scavengers (NAC and GSH) could reduce the promastigote killing by astrakurkurone. Thus the possibility of involvement of ROS and reduced glutathione in promastigote death was found confirmed as both NAC and GSH could reinstate the disruption of cell cycle phases, decreased the elevated level of ROS, lipid peroxidation and Ca2+, and restored the depletion of intracellular reduced glutathione and ∆Ψm. Our results suggest that astrakurkurone selectively induces mitochondrial dysfunction and ROS dependent death in Leishmania donovani. We claim that the present invention for the first time provides substantial in depth evidences that mushroom derived active molecules can be exploited as target specific, comparatively nontoxic (against murine splenocytes) lead for antileishmanial therapy.

SFE-INDIA/16/SEM/18 ANTICANCER ACTIVITY OF DIFFERENT PARTITIONED EXTRACTOF AERVA SANGUINOLENTA LEAVES AGAINST EHRLICH ASCITES CARCINOMA( EAC) CELL LINE Sampat Kumar Kundu 1Guru Nanak Institute of Pharmaceutical Science & Technology, Nilgunj road, Panihati, Sodepur, Kolkata, India

1, Sumana Chatterjee1, Abhijit Sen Gupta1

Flavonoids possess different biological activities such as antioxidant, anti-inflammatory, antimicrobial and hepatoprotective. Phytochemical screening of ethanolic extract obtained by soxhlation techniqueindicates the presence of flavonoid.The aim of this study is to enrich the flavonoids content present in the ethanolic extract of Aerva sanguinolenta by partition technique using various solvents such as acetone, butanol, ethanol,ethanol/water, water,



18

ethyl acetate, hexane, chloroform, dichloromethane and ethanol and to find out anticancer activity against E .A. C cell. Presence of flavonoid in each partitioned extract was confirmed by phytochemical screening and followed by thin layer chromatography using different solvents system.The content of flavonoids was determined by biochemical tests using UV-visible spectrophotometer. The first ethanol soluble fraction and 50% ethanol/water soluble fraction contains 6.57 ± 0.028mg and 6.71 ± 0.027 mg of quarcetine equivalent per gram of leaves extract respectively and the another ethanol soluble fraction which was taken from dichloromethane soluble portion contains 6.34 ± 0.022 mg of quarcetine equivalent per gram of leaves extract . The enriched 50%ethanol/water extract shows more anticancer activity against the EAC cell than the enriched fraction of first ethanol soluble fraction and enriched fraction of ethanol obtained fromdichloromethane soluble portion. SFE-INDIA/16/SEM/19 ETHNOPHARMACOLOGICAL IMPORTANCE OF HONEY Sumana Saha

1 , Ajoy Bhakat 2

1 Dept. of Kaya Chikitsa , IPGAER, SVSP, 294/3/1 A.P.C Road, Kolkata, India 2 Dept. of Roga Nidan, IPGAER, SVSP , 294/3/1 A.P.C. Road. Kolkata, India In ayurveda eight types of honey used in different ailments.Honey is a natural product of flower nectar produces by honey bee. It has been used as a food and also as a medicine as well as anupan ( vehicle) of medicine since ancient era. In the traditional system of medicine honey play a great role from birth to death. Honey act as a inhibitor for many species of disease producing agent like bacteria , fungi, virus etc . In ayurveda honey consider as a natures gift to mankind . The multi dimentional action of honey is a thirst of researcher. Almost all type of diseases that may be physical or psychological honey is used as a medicine or vehicle of medicine internally or externally. SFE-INDIA/16/SEM/21 REVIEW ON PHARMACOLOGICAL ACTIVE CONSTITUENTS OF BAUHINIA ACUMINATA (FAMILY: FABECEAE) Ipsita Sen1

, Asis Bala1, Lopamudra Datta1, Abhijit Sengupta1

Guru Nanak Institute of Pharmaceutical Science and Technology, Nilgunj Road, Panihati, Sodepur, Kolkata, India Bauhinia acuminata is a medicinal plant belongs to the family- Fabeceae and subfamily-Caesalpineaceae that occurs widely in deciduous forests. Leaves of this plant contains major active constituents that have pharmacological benefits. The constituents screened were alkaloids, flavonoids, glycosides, saponin, steroids and tannin. Paper chromatography of flavonoids shows the presence of Kaempferol, Quercetin and Apigenin. Kaempferitin plays the main role as active compound showing anti-diabetic property. Nineteen different chemical compounds were identified: β-Caryophyllene, a-Humulene, Isomethyl-a-ionone, b-Ionone, a-Farnesene, 1,6,10-Dodecatrien-3-ol, 3-Hexen-1-ol, Caryophyllene oxide, Humulene epoxide (II), Caryophylla-4(12),8(13)-dien-5a-ol, Caryophylla-4(12),8(13)-dien-5b-ol, a-Murolol, a-Cadinol, Isoaromadendrene epoxide, Farnesol, 1-Octadecene, Phytol, Sclareolide, Octacosane within the leaf extract. Among these some of the major constituents identified are Phytol (65.90%), Sesquiterpenoids: β-caroyphyllene (13.87%) and Caryophyllene oxide (3.15%). The crude extract shows hemolytic activity against human erythrocytes in a dose-dependent manner. Phytol is as a precursor for the manufacture of vitamins E and K. β-Caryophyllene is a natural bicyclic sesquiterpene with a rare cyclobutene ring, that is usually found in nature as a mixture with a-humulene (a-caryophyllene) and isocaryophyllene and it is known for its anti-inflammatory and local anesthetic activities. Taken together it may conclude that Bauhinia acuminate and its active constituents may light the new in ethno pharmacological research in future.



19

SFE-INDIA/16/SEM/22 ETHNOPHARMACOLOGICAL STUDY OF KAPARDAK Ajoy Bhakat

1 , Sumana Saha2

1 Dept.of Roga nidan, IPGAER, SVSP , 294/3/1 A.P.C Road , Kolkata, India 2 Dept. of Kaya chikitsa ,IPGAER, SVSP, 294/3/1 A.P.C. Road, Kolkata, India Ayurveda is the science of life practiced by ancient Aryans which is based on Atharva veda. Ayurvedic compound formulation are divided into two groups –a. Rasausadhi which is predominantly minerals and metals .b.Kastsusadhi which is predominantly plant. Cypraea moneta ( kapardak) is found in sea mainly in Indian and Pacific ocean. In rasasastra varieties of kapardak are mentioned on the basis of its weight, size and colour . kapardak contain carbonate of calcium , magnesium phosphate , manganege , fluride and sodium chloride .Kapardak is used to prepare medicine since ancient days in ayurveda . It has active role on asthivaha srotadusti, annavaha srota disease . SFE-INDIA/16/SEM/23 ETHNO PHARMACOLOGICAL REVIEW ON THE PLANT HAVING ANTIOXIDANT AND ANTI-INFLAMMATORY ACTIVITY IN HUMAN RED BLOOD CELLS (HRBC) Sourav Das1

, Asis Bala1, Prerona Saha1

1Guru Nanak Institute of Pharmaceutical Science and Technology 157/F, Nilgunj road, Panihati, Kolkata, India Chronic inflammation is a prolonged pathological condition characterised by mononuclear cell infiltration, tissue destruction and fibrosis due to excess production of free radicals. There are so many plant extracts which are used as anti oxidants, which helps by inhibiting the production of free radical formation in hRBC. The objective of the review is to explore the plants having cytoprotectice role on hRBC. Methanolic extract of Drypetes sepiaria (Euphorbiaceae) showed free radical scavenging activity compared to vitamin C (standard). Methanolic extract was able to inhibit inflammation about 85-90%. Methanolic leaf extract of Mimusops elengi L showed HRBC membrane stabilizing method using vitamin C as standard. The extract exhibits stabilizing activity of 69.13±0.78 at 100mcg/ml. Methanolic extract of Enicostemma axillare was used as anti inflammatory agent by showing a positive result in treatment of heat induced hemolysis and hypotonicity induced hemolysis. Hydroalcoholic extract of Strychnos potatorum linn seed have shown a very good positive anti inflammatory activity by hRBC membrane stabilization method. The ex vivo anti inflammatory activity of Lagerstroemia speciosa ethyl acetate and ethanol extracts at 50 mcg/ml showed 37.5% and 30.01% protection of hRBC solution. Maximum protection was produced by ethyl acetate was at 100 mcg/ml(54.5%), whereas ethanolic extract showed 52.94% protection at 200mcg/ml. While diclofenac 50 mcg/ml showed 52.8% protection. Ethanolic extract of Mangifera indica showed maximum protection 60.01% at 100mcg/ml. And the ethyl acetate extract showed maximum protection of 45.8% at 200mcg/ml concentration. Thus to protect oxidative stress in hRBC plants plays a pivotal role.



20

SFE-INDIA/16/SEM/24

SUCCESSFUL THERAPY OF MURINE VISCERAL LEISHMANIASIS WITH ASTRAKURKURONE, A TRITERPENE ISOLATED FROM MUSHROOM ASTRAEUS HYGROMETRICUS, INVOLVES THE INDUCTION OF PROTECTIVE CELL MEDIATED IMMUNITY AND TLR9.

Suvadip Mallick1, Aritri Dutta

1, Ankur Chaudhuri2, Debasri Mukherjee3, Somaditya Dey1, Subhadra Halder1, Joydip Ghosh1, Debarati Mukherji1, Gunjan Biswas4, Soumya Chatterjee4, Tapan Kumar Lai4,5, Pradyumna Patra1,6, Sibani Chakraborty2, Bhaskar Saha3, Krishnendu Acharya4 and Chiranjib Pal1 1Cellular Immunology and Experimental Therapeutics Laboratory, Department of Zoology, West Bengal State University, Barasat, West Bengal, India 2Department of Microbiology, West Bengal State University, Barasat, West Bengal, India 3National Centre for Cell Science, Ganeshkhind, Pune, Maharashtra, India 4Molecular and Applied Mycology and Plant Pathology Laboratory, Department of Botany, University of Calcutta, Kolkata, India 5Department of Chemistry, Vidyasagar Evening College, Kolkata, India 6Canning Sub-divisional Hospital, Canning, South 24 Parganas, West Bengal, India.

In continuation with our line of investigations for novel target specific antileishmanial leads, earlier we revealed that astrakurkurone selectively elevated the ROS leading to mitochondrial dysfunction mediated apoptosis in promastigotes. To further strengthen our investigation on astrakurkurone as anti-leishmanial lead, we found that the in vivo administration could reduce the parasite load both in spleen and liver of L. donovani-infected BALB/c mice with concomitant induction of CD4+ IFN-γ+ and CD4+ IL-17+ T cell mediated immunity. The molecule also induced the expression of co-stimulatory molecules in bone marrow derived dendritic cells and infected-macrophages in vitro with simultaneous release of pro-inflammatory cytokines. Interestingly, astrakurkurone was found to induce the expression of TLR9 in L. donovani-infected macrophages. Pre-treatment with bafilomycin A1 (TLR9 antagonist) alone and in addition with astrakurkurone reduced the parasite killing, suggesting the involvement of TLR9 which can be further strengthened by the fact that CpG ODN (TLR9 agonist) enhanced the anti-amastigote potential of astrakurkurone. A closer view of receptor-ligand interactions of TLR9-astrakurkurone as revealed from docking studies indicated that the best binding energy pose of astrakurkurone is present inside a loop comprising residues 99-111 of mouse TRL9. This region of TLR9 is the leucine rich repeat 2 (LRR2) segment. Astrakurkurone could also induce the proliferation of CD4+ T cells of active VL patients, in vitro. We may claim that this is the first convulsive report of its kind to establish mushroom derived astrakurkurone as a leishmanicidal molecule whose administration not only curbs the parasite infection, but also enhances the immune effectiveness of host cells.

SFE-INDIA/16/SEM/25

PREVALENCE OF DISEASES AMONG OLDER PATIENTS ATTENDING AYURVEDIC GERIATRICS HEALTH CARE CLINIC AT KOLKATA

Arvind Kumar Gupta1 National Research Institute of Ayurvedic Drug Development, Kolkata, India

1, Rohit Kumar Ravte1, Achintya Mitra1, Jayram Hazra1

Projection of elderly population in India would rise to about 324 million by 2050. Already being tagged “an ageing nation” with 7.7% of its population 60 years and older. Currently the elderly faces sets of medical, social, and economic problems and there is need to highlight the medical and socio-economic problems, and strategies for bringing about an improvement in their quality of life also need to be explored. To assess the prevalence of diseases among elderly at Ayurvedic Geriatrics Healthcare Clinic (GHCC) in Kolkata. Retrospective cross-sectional study was carried out among elderly patients attending GHCC of National Research Institute of Ayurvedic Drug Development, Kolkata between 2009 and 2015. Diagnoses of the patients were on the basis of clinical presentation along with laboratory investigations. After that they were provided treatment according to Ayurvedic principles and practice for care and support. A total of 28149 patients attended the GHCC from 2009-2015 for restoration of their health. Patients were mainly suffering from chronic degenerative life style disorders which included diagnosed cases of Sandhivata (Osteoarthritis) 30.30%, Vatavyadhi (Neuromuscular Diseases) 14.79%, Madhumeha (Type 2 Diabetes Mellitus) and its associate complications 10.84%, Grahani Roga (Irritable bowel syndrome) 2.54%, Amavata (Rheumatoid Arthritis)



21

2.25%, Arsha (Haemorriods) 2.08%, Vibandha (Constipation) 1.65% etc. Chronic degenerative lifestyle disorders are affecting the aged and gradually prevalence is increasing. Strategies for improving elderly health care services must be focused at improving the quality-of-life of the elderly by holistic approach through Ayurveda. SFE-INDIA/16/SEM/26

DEVELOPMENTS OF STANDARD OPERATING PROCEDURE OF MORINGA OLEIFERA LAM. (SHIGRU) BARK WITH SPECIAL REFERENCE TO AYURVEDIC PHARMACOPOEIA

Banani Das1, S. Dutta1, D. N. Mondal1, A. Saha1, Achintya Mitra2, S. N. Upadhya2, J. Hazra2

1Deptt. of R.S.& B.K, R.G.M.Ay.Collage and Hospital, Belley-sankarpur, Kushdanga, 24Pgs(N), West Bengal, India 2National Research Institute of Ayurvedic Drug Development, Kolkata, India

Ayurvedic system of medicine deals with both the preventive and curative aspects of life in a most comprehensive way and presents a close similarity to the WHO’s concept of health propounded in the modern era. The cost of the therapy is affordable and safe of plants and approximately has more than 25000 plants species. Charaka Samhita describes due to uses of several herbs for the treatment of ailments. India is endowed with rich source about 600 drugs of plant origin. Unfortunately Ayurvedic System of Medicine is on the verge of wiped out due to climatic changes and huge uses of pesticides. As a result traditional skills and wisdom have almost entirely disappeared or are in the process of disappearing as the knowledge has not been documented properly or standardized. Pharmacopoeial standardization of Ayurvedic medicines both for single and compound drugs is essential. If Ayurvedic Medicines is not standardized then prescriptions and practices are not sustained by the later generations. According to Ayurvedic Pharmacopeia of India Standard Operating Procedure (SOP) consist of Pharmacognostical study, physico-chemical parameters, and HPTLC profiles, can be good tools for standardization and validation of plants. Moringa oleifera Lam. (Shigru) is a multipurpose tree with significant medicinal and nutritional value. Moringa belonging to the Moringaceae family and has many uses of every part of the tree, such as natural antibiotic, an aid in childbirth, for treating liver disorders, urinary disorders, oedema and many other uses. The bark is widely used as emmenagouge, rubefacient, anticancerous, antitubercular, antifungal, appetizer, digestive, cardiac and circulatory stimulant. It is necessary to sure the authenticity of the crude drug when it is used for therapeutic purpose. Pharmacognostical study, Physico-chemical parameters and HPTLC profile are good tools for standardization, authentication and validation of medicinal plants. The present study was under taken for systemic pharmacognostical evaluation of the bark of the Moringa oleifera Lam. (Shigru) with respect to macroscopy, microscopy and physic-chemical parameters. The HPTLC profile was develop with ethanol and chloroform extract of the bark. To develop and used these established Standard Operating Procedures (SOP) and parameters for identification and authentication of crude bark of Moringa oleifera Lam. (Shigru). SFE-INDIA/16/SEM/27 ETHNOPHARMACOLOGY OF SARACA ASOCA- A WONDERFUL MEDICINAL TREE

Shrabani Latua1Bengal Institute of Pharmaceutical Sciences, Kalyani, Nadia, West Bengal, India

1, Monojit Debnath1, Moulisha Biswas1

Saraca asoca is an important indigenious plant with lots of traditional importance belonging to the family Caesalpinaceae found throughout India especially in Himalaya, Kerala, and Bengal & whole south region. It is the most ancient tree of India generally known as “Ashok briksha”& it’s a Sanskrit word literally means “without sorrow” or which gives no grief. Ashok is one of the most legendary plants & specially sacred to Hindu God of love, Kamdeva, for whom it is worshipped every year on 27th December. It is mentioned in Hindu mythology as the Ashok tree, beneath which the Indian philosopher & founder of Buddhism, Goutam Siddhartha was said to have been born under the tree. These are the wonderful herb that claims to cure several diseases according to Ayurvedic treatises. This versatile plant is the source of various types of compounds like glycoside, flavonoids, tannin& saponin which are having various pharmacological activities like anti-spasmogenic, anti-bacterial, anti-tumor, anti-estrogenic, anti-oxytocic, anti-cancer & anti-menorrhagic activity & have extend uses in Ayurveda, Unani & Homeopathy and other integrated medicinal



22

systems. Ashok arishta is reliable medicine used to treat gynecological disorder like menorrhagia. It is used to treat skin infection, CNS function & it’s bark acts on muscular fibers of the uterus. The extract of bark partially prevented the decreases in body weight, haemoglobin levels & leucocytes count. From all these sides it may be concluded that it is having the potentiality to treat a number disease and having a focused historical importance also. SFE-INDIA/16/SEM/30 AYURVEDIC PERSPECTIVE ON AMAVATA WITH RESPECT TO RHEUMATOID ARTHRITIS

Bodhisattwa Bakuli1

1Department of kaya chikitsa, Institute of Post Graduate Ayurvedic Education & Research, Shyamadas Vaidya Shastra Pith, Kolkata

Amavata is a disease which is caused by aggravation or vitiation of vayu associated with ama. This vitiated vayu with ama circulate all over the body through dhamani and take lodge into sleshma sthana (amasaya, sandhi) and produce various symptoms like stiffness, pain, tenderness etc. and make a person lame. The symptom of amavata is identical to rheumatism which include rheumatoid arthritis. Rheumatoid arthritis is an auto-immune non supurative inflammation of small joints. RA term 1st mentioned by Alfred berring Garrod (1819-1960) in the year of 1887 made him got knight award. Amavata is a crippling disease causing maximum loss of human power. It’s not only a disease of locomotor system it’s a systemic disorder and it’s named after pathogenic constituent which are ama and vata. The main causative factor of this disease is ama which is caused due to malfunctioning of digestive and metabolic mechanism. The disease is occurred due to intake of virudhya ahar. This virudha ahar produces mandagni. The mandagni causes formation of ama. So in this disease these two are chief pathognomic factors that are ama and vata. Kapha and pitta are invariably involved in its samprapti. Ama and the vata are being contradictory in their characteristics there is difficulty in planning their line of treatement. Derrangement of kapha dosh specially sleshmak kapha especially involved in amavata. Which produces joint pain, swelling and tenderness can be correlated with Rheumatoid arthritis. Severe dreadful diseases are prevalent in medical science. The scope of therapeutic measures is limited even after extreme advancement of modern bio-medical science, rheumatological disorder is a group of disease has no specific type of management. Amavata is a disease which is mentioned in ayurveda in madhav nidan as a disease entity but charak samhita also mentioned amavata as an indication of kangsa haritaki (Tri sathiya chikitsa cha. Chi 12). Amavata is a vata kaphaja disorder. Hence in defferent classic mentioned so many drugs regarding amavata but the disease is not cured due to intake of etilogical factor (virudha ahar) so our aim is searching for standard and suitable drugs for amavata. Although some achariya mentioned snehapana in the management of amavata. But snehapana is not given in the treatment of amavata because sneha increases ama. But in present era some physicans are giving snehapana in amavata in nirambastha and getting significant result. SFE-INDIA/16/SEM/31 OBESITY AND ITS AYURVEDIC MANAGEMENT

1Ashutosh Dubey 1Department Of Kayachikitsa, Institute of Post Graduate Ayurvedic Education & Research, Kolkata, India Obesity is a nutritional metabolic disorder characterized by excessive accumulation of fat in fat depots commonly seen in rich communities and persons leading sedentary lifestyle. It can be diagnosed by body mass index. The risk factors of this disease being diabetes mellitus, coronary heart disease, G. B stone, hypertension, atherosclerosis, etc resulting in lowering the lifespan of an individual. In Ayurveda this disease can be compared with sthaulya which has been stated as first mahagada in astamahagada and is caused due to excessive accumulation of mamsa and meda dhatu having being categorized under Kaphaja nanatmaja vyadhi. For the treating sthualya the main treatment is guru and apatarpana but different treatment modalities can be adopted by sodhana therapies like vamana, virechana, vasti, etc. and samana therapies by administering drugs like medohara guggulu, navaka guggulu depending on the prakriti of the individuals.



23

SFE-INDIA/16/SEM/32 URINARY STENT ENCRUSTATIONDISSOLUTION ACTIVITY OF PARNABEEJA AND VARUNA IN WISTAR RAT- AN EXPERIMENTAL EVALUATION

L.D.Barik1, K.K.Ratha1, A.K.Panda1, D.Das1, J.Hazra2

1National Research Institute of Ayurvedic Drug Development, CCRAS, Ministry of AYUSH, Bidhannagar, Kolkata, India

A hard mass deposited in the urinary biomaterials forms mostly of oxalate, phosphates and urate crystals, which can causes bleeding, obstruction, infection and pain in the abdomen, flank, or groin region. After placement of the stent for the urinary anatomical or pathological deformities, over a period of 1 to 2 months, it requires to remove the stent due to development of encrustation resulting further obstruction of the urinary system. So these patients have no option except frequent replacement.The formation of various types of urinaryencrustation is strongly influenced by urinary pH. An alkaline pH favors the crystallization of calcium- and phosphate-containing encrustation, whereas acidic urine pH promotes uric acid or cysteineencrustation. To evaluate the effect of an Ayurvedic drug on dissolution of encrustation in urinary system. The study was conducted at IMS, BHU, Varanasi. 40 wistar albino rats of either sex were taken for the study and were divided in to three groups (control,preventive and treated groups). Dried aqueous extract of Bryophyllumpinnatum and Crataevanurvalain equal quantity at dose of 175 mg/kgbwadministered to the animals of preventive and treated groups. Serum and urinary electrolytes of the Albino rats was evaluated before and after, surgically placement of the stent. The result of the study shows efficacy of the Bryophyllum pinnatum and Crataevanurvalaaqueous extract in preventing as well as curative aspect of encrustation.

SFE-INDIA/16/SEM/33 NETWORK PHARMACOLOGY ANALYSIS OF ALABU (LAGENARIA SICERARIA): A PRELIMINARY REPORT.

Subhadip Banerjee1, Logesh Rajan1, Amarendra Tiwari1, Pritorthi Rajarshi Biswas1, Joydeb Chanda1 Amit Kar1, Debayan Goswami1, Pulok K Mukherjee1 1School of Natural Product Studies, Dept of Pharma Tech. Jadavpur University

Network pharmacology is an emerging technique, which integrates systems biology and computational biology to study multi-component and multi-targeted formulations. Ayurveda, the traditional system of Indian medicine mentions multiple uses of herbs however; their scientific rationale and mechanisms remain largely unexplored. This presents work explores the preliminary potential of network pharmacology to understand the rationale of a commonly used Ayurvedic herb Alabu (Lagenaria siceraria) of the family Cucurbitaceae . We have developed target networks of Lagenaria siceraria based on the information gathered from different databases and using the software Cytoscape 3.3.0. The networks depict the interaction of bioactives with molecular targets and their relation with pathways as analysed from Reactome Pathway Database. The network pharmacology analysis of Lagenaria siceraria has offered new relationships among bioactives, targets and pathways. The analysis found about 51 targets iteracting with a single compound. Whereas certain novel compounds were also found targets for which is not predictable. This pioneering effort might open new possibilities to know pharmacodynamics of Ayurvedic drugs like Lagenaria siceraria and also help in the discovery of new leads and targets for various diseases.

2nd convention front cover - ethnopharmacology

Documents